ERS 2025 at a glance

Ahead of ERS 2025 in Amsterdam, get concise highlights across COPD, asthma, bronchiectasis, pulmonary hypertension, sleep and rehab, oncology, and AI/ML—curated by LucidQuest.

📅 Build your schedule around the topics that interest you. 📥 Download the ERS 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From Notable Presentations

COPD and Asthma Management

  • Dupilumab: Reduced exacerbations and oral corticosteroid (OCS) use.

  • SSGJ-611: Improved lung function in T2 COPD.

  • 3% hypertonic saline: Reduced bronchiolitis severity and hospitalizations.

Bronchiectasis Treatments

  • Brensocatib: Reduced pulmonary exacerbations and preserved FEV1/FVC.

  • Gremubamab: Improved cough, breathlessness, and sputum in P. aeruginosa bronchiectasis.

Pulmonary Hypertension

  • Inhaled treprostinil: Outperformed PDE5 inhibitors for ILD-PH survival.

  • BPA: Improved hemodynamics and symptoms in inoperable CTEPH.

  • Cough therapy: Improved quality of life.

Lung Function & Rehabilitation

  • Pre-habilitation respiratory muscle training: Reduced complications and length of stay.

  • PR-buddies: Improved COPD rehabilitation adherence and exercise capacity.

Trials & Patient Experience

  • LLN spirometry thresholds: Cut 72% IPF screening failures.

  • Synthetic controls: Showed Buloxibutid FVC gains.

  • PREDMETH and IMP2ART: Highlighted implementation gaps.

Sleep Apnea

  • CPAP: Remained effective for AHI and sleepiness.

  • O2Vent Optima + ExVent: Cut AHI 71% (84% success).

  • BHNS: Reduced AHI in CPAP-intolerant patients.

Lung Cancer & Oncology

  • TGR5 inhibition + PD-1 blockade: Improved NSCLC outcomes.

  • Envafolimab + etoposide/carboplatin: Showed SCLC potential.

  • Pre-habilitation: Reduced postoperative complications.

Artificial Intelligence and Machine Learning at ERS 2025

Chronic Cough Monitoring

  • CoughCheck™: Trained on 3,099 hours, achieved 94.3% precision for event detection, enabling automated cough monitoring in clinical workflows.

Bronchoscopy Lesion Detection

  • BronchoAI: Delivered 94–98% anatomical recognition and 78–93% lesion detection accuracy, enhancing guidance and efficiency for bronchoscopists.

CTEPH Prognostication

  • AI-derived thromboembolic volume: Correlated with pulmonary vascular resistance and mortality risk (p < 0.001), improving risk stratification in CTEPH.

Multi-Modal COPD Diagnosis

  • Cough acoustics + demographics/symptoms: Achieved AUROC 0.96, generalizing across severities and subgroups.

Spirometry With Large Models

  • ChatGPT-4o: Showed highest agreement (κ = 0.48) with pulmonologists for spirometry interpretation—useful for workflow support while needing refinement.

📅 Build your schedule around the topics that interest you.

📥 Download the ERS 2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.

Privacy Preference Center